Diabeteszentrum Bad Lauterberg, Kirchberg 21, D-37431 Bad Lauterberg im Harz, Germany.
Ann Intern Med. 2012 Dec 4;157(11):767-75. doi: 10.7326/0003-4819-157-11-201212040-00004.
Recent biochemical diagnostic guidelines for insulinomas require demonstration of hypoglycemia with inappropriately elevated (nonsuppressed) insulin, C-peptide, or proinsulin, but these criteria may overlap with those in patients without insulinomas. Use of an "amended" insulin-glucose ratio that accounts for the normal variation in insulin secretion according to prevailing glycemia may improve diagnostic accuracy.
To compare the diagnostic accuracy of current diagnostic guideline criteria with the amended insulin-glucose ratio in patients with a suspected insulinoma.
Retrospective cohort study.
2 specialized university departments in Germany.
114 patients with suspected hypoglycemia over 10 years having diagnostic prolonged fasts.
Glucose, insulin, C-peptide, and the amended insulin-glucose ratio were measured during and at discontinuation of prolonged fasts.
Of 114 patients who were evaluated, 49 had surgical resection of histologically confirmed insulinomas. Insulinoma was excluded in 65 patients; follow-up for a mean of 10 years (range, 0 to 16 years) showed no progressively severe hypoglycemic events or diagnoses of insulinoma. Patients with insulinoma had lower glucose levels and higher insulin and C-peptide levels overall than did control patients at the end of prolonged fasts, but there was considerable overlap. The amended insulin-glucose ratio correctly identified 48 of 49 patients with insulinoma and excluded the diagnosis in 64 of 65 control patients, resulting in positive and negative predictive values of 0.98 (95% CI, 0.89 to 1.00) and 0.99 (CI, 0.92 to 1.00), respectively, compared with 0.75 (CI, 0.63 to 0.85) and 0.98 (CI, 0.89 to 1.00), respectively, for glucose, insulin, and C-peptide concentration criteria.
The study had a retrospective design, no proinsulin concentrations were available, and a nonspecific insulin immunoassay (crossreactive with proinsulin) was used.
The amended insulin-glucose ratio showed improved diagnostic accuracy over established criteria that use glucose, insulin, and C-peptide concentrations.
None.
最近的胰岛素瘤生化诊断指南要求在低血糖的情况下,胰岛素、C 肽或胰岛素原水平升高(无抑制),但这些标准可能与没有胰岛素瘤的患者重叠。使用根据血糖水平正常变化校正胰岛素分泌的“修正”胰岛素-葡萄糖比值可能会提高诊断准确性。
比较当前诊断标准与疑似胰岛素瘤患者修正胰岛素-葡萄糖比值的诊断准确性。
回顾性队列研究。
德国两所专门的大学系。
114 例疑似低血糖患者,10 年来接受诊断性长时间禁食。
在长时间禁食期间和禁食结束时测量血糖、胰岛素、C 肽和修正胰岛素-葡萄糖比值。
在 114 例接受评估的患者中,49 例接受了组织学证实的胰岛素瘤切除术。65 例患者排除了胰岛素瘤;平均随访 10 年(范围 0 至 16 年),未出现逐渐加重的严重低血糖事件或胰岛素瘤诊断。与对照组相比,胰岛素瘤患者在长时间禁食结束时血糖水平较低,胰岛素和 C 肽水平较高,但存在相当大的重叠。修正的胰岛素-葡萄糖比值正确识别了 49 例胰岛素瘤患者中的 48 例,并排除了 65 例对照组患者中的 64 例诊断,阳性预测值和阴性预测值分别为 0.98(95%CI,0.89 至 1.00)和 0.99(CI,0.92 至 1.00),而血糖、胰岛素和 C 肽浓度标准的阳性预测值和阴性预测值分别为 0.75(CI,0.63 至 0.85)和 0.98(CI,0.89 至 1.00)。
该研究为回顾性设计,没有检测到胰岛素原浓度,并且使用了一种非特异性胰岛素免疫测定法(与胰岛素原交叉反应)。
修正的胰岛素-葡萄糖比值在使用血糖、胰岛素和 C 肽浓度的既定标准上显示出了提高的诊断准确性。
无。